Cargando…
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood
INTRODUCTION: We examined longitudinal cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker changes among cognitively normal individuals with 10.7 years follow‐up, on average. METHODS: Analyses included 278 participants (M age = 57.5 years); 94 have progressed from normal cognition to m...
Autores principales: | Pettigrew, Corinne, Soldan, Anja, Wang, Jiangxia, Wang, Mei‐Cheng, Greenberg, Barry, Albert, Marilyn, Moghekar, Abhay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673459/ https://www.ncbi.nlm.nih.gov/pubmed/36415591 http://dx.doi.org/10.1002/dad2.12374 |
Ejemplares similares
-
Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease
por: Pettigrew, Corinne, et al.
Publicado: (2017) -
Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020) -
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019) -
Regional White Matter Hyperintensities and Alzheimer’s Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment
por: Newton, Princess, et al.
Publicado: (2023) -
Cortical thickness in relation to clinical symptom onset in preclinical AD
por: Pettigrew, Corinne, et al.
Publicado: (2016)